1-3 of 3
Michael Dechant, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Recombinant Dimeric IgA Antibodies as Tumor-Specific Agents.

Michael Dechant, MD, Stefan Lohse, PhD, Stefanie Derer, PhD, Thomas Beyer, PhD, Katja Klausz, PhD, Matthias Peipp, PhD, Jeanette H. W. Leusen, PhD, Jan G. J. van de Winkel, PhD, Thomas Valerius, MD
Journal: Blood
Blood (2010) 116 (21): 1488.
https://doi.org/10.1182/blood.V116.21.1488.1488
Published: 2010
Journal Articles

Recombinant Chimeric IgA1 and IgA2 Antibodies for Tumor Immunotherapy.

Michael Dechant, MD, Thomas Beyer, PhD, Stefan Lohse, Tanja Schneider-Merck, PhD, Wencke Weisner, Sven Berger, PhD, Matthias Peipp, PhD, Jan G.J. van de Winkel, PhD, Thomas Valerius, MD
Journal: Blood
Blood (2007) 110 (11): 4892.
https://doi.org/10.1182/blood.V110.11.4892.4892
Published: 2007
Journal Articles

A Humanized HLA-DR Antibody (HU1D10, Apolizumab) in Combination with G-CSF (Filgrastim) for the Treatment of Non-Hodgkin’s Lymphoma: A Pilot Study.

Juergen Rech, MD, Roland Repp, MD, Dorit Rech, MD, Bernhard Stockmeyer, MD, Michael Dechant, MD, Gerald Niedobitek, MD, Tilman Pearce, MD, Georg Weiner, MD, Martin Gramatzki, MD, Thomas Valerius, MD.
Journal: Blood
Blood (2005) 106 (11): 4775.
https://doi.org/10.1182/blood.V106.11.4775.4775
Published: 2005